# Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA Vaccine

> **NCT07400003** · PHASE1,PHASE2 · RECRUITING · sponsor: **Sinovac Biotech Co., Ltd** · enrollment: 519 (estimated)

## Conditions studied

- Herpes Zoster
- mRNA Vaccine

## Interventions

- **BIOLOGICAL:** Low-dose experimental vaccine
- **BIOLOGICAL:** High-dose experimental vaccine
- **BIOLOGICAL:** Active-controlled vaccine A
- **BIOLOGICAL:** Active-controlled vaccine B
- **OTHER:** Placebo group

## Key facts

- **NCT ID:** NCT07400003
- **Lead sponsor:** Sinovac Biotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-06
- **Primary completion:** 2026-05-31
- **Final completion:** 2027-04-30
- **Target enrollment:** 519 (ESTIMATED)
- **Last updated:** 2026-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07400003

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07400003, "Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA Vaccine". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT07400003. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*